Search research articles
Contact Us
Filters
Showing results (21-30 of 25) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 25 results.
Seminars in Oncology
|
March 1, 1977
Metastatic and histologic presentations in unknown primary cancer
J S Nystrom, J M Weiner, J Heffelfinger-Juttner, et al.
Cancer
|
May 15, 1985
Estrogen and progestin receptors in human prostatic carcinoma
R M Wolf, S L Schneider, J E Pontes, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 1, 1983
Presumptive downstaging from preoperative irradiation for bladder cancer as determined by flow cytometry: preliminary report
F A Klein, W F Whitmore, R M Wolf, et al.
Physical Review Letters
|
September 16, 2000
Difference between blocking and Néel temperatures in the exchange biased Fe3O4/CoO system
P J van der Zaag, Y Ijiri, J A Borchers, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
P J Creaven, D E Brenner, J W Cowens, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 25) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 25 results.
Seminars in Oncology
|
March 1, 1977
Metastatic and histologic presentations in unknown primary cancer
J S Nystrom, J M Weiner, J Heffelfinger-Juttner, et al.
Cancer
|
May 15, 1985
Estrogen and progestin receptors in human prostatic carcinoma
R M Wolf, S L Schneider, J E Pontes, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 1, 1983
Presumptive downstaging from preoperative irradiation for bladder cancer as determined by flow cytometry: preliminary report
F A Klein, W F Whitmore, R M Wolf, et al.
Physical Review Letters
|
September 16, 2000
Difference between blocking and Néel temperatures in the exchange biased Fe3O4/CoO system
P J van der Zaag, Y Ijiri, J A Borchers, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
P J Creaven, D E Brenner, J W Cowens, et al.
Page
of 3